BMS Expands its Collaboration with Compugen to Evaluate the Combination of COM701 + Opdivo

 BMS Expands its Collaboration with Compugen to Evaluate the Combination of COM701 + Opdivo

BMS Expands its Collaboration with Compugen to Evaluate the Combination of COM701 + Opdivo

Shots:

  • Under the amended agreement, BMS will supply its Opdivo (nivolumab) for Compugen’s P-Ib cohort expansion study to evaluate COM701 in combination with Opdivo in selected cancer indications. The study is expected to be initiated in Q2’21
  • The P-Ib study will examine fixed doses of COM701 and Opdivo, as determined by Compugen’s P-Ia combination dose escalation study. Based on Compugen’s translational analyses and preliminary antitumor activity in dose escalation, the study will enroll patients with ovarian, breast, endometrial and microsatellite-stable colorectal cancers
  • Additionally, The companies are also investigating COM701 in a triple combination study with Opdivo and BMS-986207

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Fierce Biotech

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post